title: [Effect of compound paeonol dripping pill on levels of plasma inflammatory mediators in patients with unstable angina].
abstract: OBJECTIVE
  To evaluate the clinical therapeutic effect of Compound Paeonol Dripping Pill (CPDP) and its effect on the levels of plasma inflammatory mediators, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemotactic protein-1 (MCP-1).
  
  
  METHODS
  Ninety patients with unstable angina were randomized by enveloping method into 3 groups equally, the conventional Western therapy group (A), the CPDP group (B), and the Tongxinluo group (C). The improvement of angina pectoris symptoms and electrocardiogram (ECG) was observed after 2 weeks of treatment and the levels of plasma CRP, IL-6, TNF-alpha and MCP-1 were measured before and after treatment.
  
  
  RESULTS
  The total effective rate in improving angina pectoris was 93.3% in Group B, significantly higher than that in Group A (73.3%, P <0.01) and Group C (76.7%, P <0.05), while no significant difference of ECG improvement rate was found between the three groups (P >0.05). Plasma total cholesterol and inflammation indexes were significantly lowered after treatment in Group B (P <0.05), showing a significant difference to those in the other two groups (P <0.05), but the indexes were unchanged in the other two groups (P >0.05).
  
  
  CONCLUSIONS
  Effect of CPDP is better in relieving symptoms, depressing inflammatory reaction for treatment of unstable angina patients than that of Tonxinluo Capsule and conventional Western treatment.
authors.affiliation: Department of Cardiology, General Hospital of Beijing Military Region, Beijing. wx0515@hotmail.com
authors.forename: Xian
authors.initials: X
authors.lastname: Wang
authors.forename: Da-Yi
authors.initials: DY
authors.lastname: Hu
authors.forename: Ou
authors.initials: O
authors.lastname: Sha
mesh_terms: D000098:Acetophenones / Q000008:administration & dosage / Q000627:therapeutic use*; D000789:Angina, Unstable / Q000188:drug therapy* / Q000276:immunology; D002097:C-Reactive Protein / Q000378:metabolism; D018932:Chemokine CCL2 / Q000097:blood; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D013607:Tablets; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000098:Acetophenones; D018932:Chemokine CCL2; D018836:Inflammation Mediators; D015850:Interleukin-6; D013607:Tablets; D014409:Tumor Necrosis Factor-alpha; C013638:paeonol; D002097:C-Reactive Protein